In a study of postmenopausal women with osteoporosis who were at high risk for fracture, treatment with monthly subcutaneous romosozumab (210 mg) for a year followed by weekly oral alendronate (70 mg) significantly lowered risk of new vertebral (48%) and nonvertebral (19%) than alendronate alone. These findings are reported September 11, 2017 in the New England Journal of Medicine.